Symptomatic intracranial atherosclerotic stenosis
Conditions
Interventions
Group 1:ischemic pre-conditioning
Group 2:distance ischemic preconditioning training without pressor
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 40-80 years old, male or female; 2. The selected event was ischemic stroke or transient ischemic attack (TIA) and met the following conditions: Ischemic stroke subjects were enrolled within 7 days after onset, and mRS = 4; Subjects with transient ischemic attack were enrolled within 7 days of onset, and ABCD2 = 4; 3. the subject has symptomatic intracranial responsibility atherosclerotic stenosis, and the degree of stenosis is 50%-99% [intracranial stenosis vessels include: internal carotid artery (intracranial segment), middle cerebral artery (M1 segment)), basilar artery, vertebral artery (intracranial segment)]; 4. Agree to participate in this clinical trial and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who took thrombolytic therapy within 24 hours before enrollment; 2. Those who have a progressive nervous system condition within 24 hours before admission; 3. the cerebral vein has damage and lesions; 4. intracranial artery stenosis is due to aortic dissection, moyamoya disease; any known vascular inflammatory disease; herpes zoster, varicella-zoster or other viral infections vascular disease; neurosyphilis; other intracranial infections; any cerebrospinal fluid Increased intracranial artery stenosis associated with cell growth; radiation-induced vascular disease; muscle fiber dysplasia; sickle cell disease; neurofibroma; benign vascular disease of the central nervous system; postpartum vascular disease; intracranial artery stenosis caused by vasospasm or emboli; 5. Identify any patients with the following cardiogenic embolism: rheumatic mitral or aortic stenosis, prosthetic heart valve, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, egg Open hole, left ventricular wall thrombus or valvular hernia, congestive heart failure, bacterial endocarditis, or any other cardiovascular disease that is not suitable for enrollment; 6. the patient has uncontrollable hypertension (after drug treatment, systolic blood pressure > 180mmHg or diastolic blood pressure > 110mmHg); 7. stenosis of the subclavian artery = 50% or subclavian artery stealing syndrome; 8. extracranial cerebral artery stenosis = 50%; 9. Laboratory inspection indicators are not qualified: Aspartate aminotransferase or alanine aminotransferase is 3 times higher than the upper limit of normal; Creatinine clearance 265umol/l (> 3.0mg/dl); Platelets <100 x 10^9/L; 10. Those who developed intracranial hemorrhage 90 days before enrollment (brain parenchymal hemorrhage, subarachnoid hemorrhage, subdural/external hemorrhage); 11. had suffered from intracranial tumors or cerebral aneurysms, arteriovenous malformations; 12. Those suffering from severe blood system diseases or severe coagulation disorders; Retinal hemorrhage or visceral bleeding occurred within 13 or 30 days; 14. Pre-operative large-scale surgery (including femoral artery, heart, aorta or carotid surgery) within 30 days before enrollment or 3 months after enrollment; 15. Target lesions have been treated with stenting, angioplasty or other related medical devices, or those who are expected to undergo the above treatment within 3 months after enrollment; 16. remote ischemic adaptation contraindications, such as the upper limbs have more serious soft tissue injury, fracture or vascular injury; 17. Pregnant women or women in lactation; 18. Life expectancy <3 years; 19. Unwilling to be followed up or poorly compliant; 20. Those who are participating in other clinical research, or have participated in other clinical research within 3 months before enrollment, or have participated in the research; 21. Other circumstances that the investigator believes are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The progression of stroke deteriorated within 180 days;NIHSS and mRS and Barthel scores improvement within 180 days;cerebral autoregulation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Other vascular and death events within 180 days; | — |
Countries
China
Contacts
Public ContactRen Lijie
Shenzhen Second People' Hospital
Outcome results
None listed